Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN


Goldman J. W. , Garassino M. C. , Chen Y., Reinmuth N., Hotta K., Poltoratskiy A., ...Daha Fazla

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31 identifier